Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
06 May 2016Website:
http://www.intelliatx.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:49:27 GMTDividend
Analysts recommendations
Institutional Ownership
NTLA Latest News
NEW YORK , July 2, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Intellia Therapeutics, Inc. (NASDAQ: NTLA) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Intellia (NTLA) appoints Edward Dulac as its new chief financial officer after Glenn Goddard steps down from his role with effect from Jun 30.
CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Edward Dulac as Executive Vice President, Chief Financial Officer (CFO), and Treasurer, effective July 22, 2024. Mr. Dulac will succeed Glenn Goddard who will step down from his role effective June 30, 2024.
CAMBRIDGE, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today presented new data demonstrating for the first time the potential for redosing with an investigational, in vivo CRISPR/Cas9 genome editing therapy. These data from the ongoing Phase 1 study of NTLA-2001, a single-dose treatment in development for transthyretin (ATTR) amyloidosis, were presented at the Peripheral Nerve Society Annual Meeting, taking place June 22–25 in Montreal, Canada.
- Data to offer insight into the safety and pharmacodynamics of redosing patients with a systemically delivered LNP-based CRISPR gene editing candidate - Data to offer insight into the safety and pharmacodynamics of redosing patients with a systemically delivered LNP-based CRISPR gene editing candidate
CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Brian Goff to its board of directors.
Intellia's (NTLA) lead genome-editing candidate, NTLA-2001 being developed to treat transthyretin (ATTR) amyloidosis, holds promise. Other pipeline candidates are also progressing well.
Intellia Therapeutics has a gene editing therapy that looks to be quite effective. That's favorable for the program's chances of getting approved.
Intellia Therapeutics has released positive data from its Phase I/II study of NTLA-2002, a CRISPR-based gene editing therapy. The study shows promising results for in vivo gene editing, offering potential treatments for genetic diseases. Robust target engagement and efficacy data pave the way for future Phase II results from Intellia later this year.
Intellia (NTLA) gains 10% after reporting encouraging long-term efficacy data from the phase I portion of its early to mid-stage study evaluating NTLA-2002 for treating hereditary angioedema.
What type of business is Intellia Therapeutics?
Intellia Therapeutics, Inc. is a biotechnology company that focuses on developing therapeutic treatments based on genome editing (CRISPR/Cas9 technology). The company was founded in 2014. Its headquarters, offices, and laboratories are located in Cambridge, Massachusetts. The technology being developed by Intellia has the potential to transform modern medicine by allowing the editing of disease-related genes in one treatment, creating new engineered cell therapy methods that can replace a patient's sick cells or effectively target various types of cancer and autoimmune diseases. The company is harnessing its full potential to develop a potentially new class of therapeutic products for patients with severe and life-threatening illnesses.
What sector is Intellia Therapeutics in?
Intellia Therapeutics is in the Healthcare sector
What industry is Intellia Therapeutics in?
Intellia Therapeutics is in the Biotechnology industry
What country is Intellia Therapeutics from?
Intellia Therapeutics is headquartered in United States
When did Intellia Therapeutics go public?
Intellia Therapeutics initial public offering (IPO) was on 06 May 2016
What is Intellia Therapeutics website?
https://www.intelliatx.com
Is Intellia Therapeutics in the S&P 500?
No, Intellia Therapeutics is not included in the S&P 500 index
Is Intellia Therapeutics in the NASDAQ 100?
No, Intellia Therapeutics is not included in the NASDAQ 100 index
Is Intellia Therapeutics in the Dow Jones?
No, Intellia Therapeutics is not included in the Dow Jones index
When does Intellia Therapeutics report earnings?
The next expected earnings date for Intellia Therapeutics is 02 August 2024